Javascript must be enabled to continue!
Chitosan-covered tamponade for the treatment of postpartum hemorrhage: a registry-based cohort study assessing outcomes and risk factors for treatment failure
View through CrossRef
Abstract
Background
Postpartum hemorrhage (PPH) is one of the leading causes of maternal morbidity and mortality worldwide. Intrauterine hemostatic devices are recommended when PPH does not respond to medical treatment. The objective of this study was to assess the factors leading to unsuccessful intrauterine therapy with a chitosan-covered tamponade (CT) for the treatment of PPH and to evaluate clinical outcomes based on real-world data.
Methods
This registry-based cohort study included all women treated with CT for PPH between January 2017 and June 2022 at a university clinic’s perinatal department. The endpoint was defined as the failure of CT, indicated by the requirement of further invasive procedures for ongoing hemorrhage after CT application. Medical records were reviewed and binary logistic regressions used to evaluate delivery mode, placenta previa, and placenta accreta spectrum as potential risk factors for CT treatment failure.
Results
The cohort consisted of 230 women, with successful CT treatment in 91.3%. The success rate for mild PPH was 100.0%, for moderate 95.5%, and for severe 84.2%. Five hysterectomies were performed in total. Placenta previa in cesarean sections was identified as the primary risk factor for CT treatment failure, increasing the odds about 7.5-fold (Odds Ratio: 7.48; 95% CI: 1.87–33.15) compared to cesarean sections without placenta previa. Furthermore, delays in CT insertion may also contribute to treatment failure.
Conclusion
CT serves as an intrauterine treatment for medically intractable PPH. Placenta previa significantly increases the risk of CT treatment failure in cesarean sections. Obstetricians should be particularly vigilant in managing patients with placenta previa and consider early use of CT or a combination of procedures.
Trial registration
This study was approved by the local Ethics Committee on 11/10/2021 (EA4/231/21).
Springer Science and Business Media LLC
Title: Chitosan-covered tamponade for the treatment of postpartum hemorrhage: a registry-based cohort study assessing outcomes and risk factors for treatment failure
Description:
Abstract
Background
Postpartum hemorrhage (PPH) is one of the leading causes of maternal morbidity and mortality worldwide.
Intrauterine hemostatic devices are recommended when PPH does not respond to medical treatment.
The objective of this study was to assess the factors leading to unsuccessful intrauterine therapy with a chitosan-covered tamponade (CT) for the treatment of PPH and to evaluate clinical outcomes based on real-world data.
Methods
This registry-based cohort study included all women treated with CT for PPH between January 2017 and June 2022 at a university clinic’s perinatal department.
The endpoint was defined as the failure of CT, indicated by the requirement of further invasive procedures for ongoing hemorrhage after CT application.
Medical records were reviewed and binary logistic regressions used to evaluate delivery mode, placenta previa, and placenta accreta spectrum as potential risk factors for CT treatment failure.
Results
The cohort consisted of 230 women, with successful CT treatment in 91.
3%.
The success rate for mild PPH was 100.
0%, for moderate 95.
5%, and for severe 84.
2%.
Five hysterectomies were performed in total.
Placenta previa in cesarean sections was identified as the primary risk factor for CT treatment failure, increasing the odds about 7.
5-fold (Odds Ratio: 7.
48; 95% CI: 1.
87–33.
15) compared to cesarean sections without placenta previa.
Furthermore, delays in CT insertion may also contribute to treatment failure.
Conclusion
CT serves as an intrauterine treatment for medically intractable PPH.
Placenta previa significantly increases the risk of CT treatment failure in cesarean sections.
Obstetricians should be particularly vigilant in managing patients with placenta previa and consider early use of CT or a combination of procedures.
Trial registration
This study was approved by the local Ethics Committee on 11/10/2021 (EA4/231/21).
Related Results
Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
In this study, porous scaffolds were fabricated using inorganic material-hydroxyapatite and chitosan for bone-tissue engineering. The combination of hydroxyapatite and chitosan may...
Primary postpartum hemorrhage and associated factors among delivering women in Gedeo Zone, Southern Ethiopia
Primary postpartum hemorrhage and associated factors among delivering women in Gedeo Zone, Southern Ethiopia
IntroductionPrimary postpartum hemorrhage is still the main cause of maternal death worldwide, especially in low-resource nations like Ethiopia where there are insufficient healthc...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
BIODEGRADATION OF CHITOSAN MEMBRANE SCALES OF HARUAN FISH (Channa striata)-HYDROXYAPATITE IN ARTIFICIAL SALIVA SOLUTION
BIODEGRADATION OF CHITOSAN MEMBRANE SCALES OF HARUAN FISH (Channa striata)-HYDROXYAPATITE IN ARTIFICIAL SALIVA SOLUTION
Background: Membrane materials for surgical procedures using Guided Tissue Regeneration (GTR) are Polytetrafluoroethylene (PTFE) and collagen, but have the disadvantage of requirin...
Intrauterine Postpartum Hemorrhage-Control Devices
Intrauterine Postpartum Hemorrhage-Control Devices
Postpartum hemorrhage, defined as a cumulative blood loss of 1,000 mL or more or blood loss associated with signs or symptoms of hypovolemia regardless of the route of delivery, is...
Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo
Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo
AbstractIn this study, chitosan and alginate were selected to prepare alginate/chitosan nanoparticles to load the drug lovastatin by the ionic gelation method. The synthesized nano...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Development and implementation of an “Internet ” integrated service model for antepartum, intrapartum, and postpartum care in maternal and child specialty hospitals: A randomized controlled trial
Development and implementation of an “Internet ” integrated service model for antepartum, intrapartum, and postpartum care in maternal and child specialty hospitals: A randomized controlled trial
Objective
This study investigates the effects of developing and implementing an integrated service model for antepartum, intrapartum, and postpartum care in maternal an...

